Drugs / β-elemene
Trials 2 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 21 trial | ||||||
| Phase 2 | NCT03123484 | Apr 2017 → Apr 2019 | non-small cell lung carcinoma | China Medical University, China | Unknown | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT02629757 | Apr 2015 → Apr 2020 | anaplastic astrocytoma, anaplastic oligoastrocytoma, glioblastoma | Sun Yat-sen University | Unknown | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | β-elemene | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03123484 ↗ |
| Route | Intravenous | “β-elemene 600mg/d,ivdrip,d1-14,every 28 days for 1 cycle, totally 6 cycles” NCT02629757 ↗ |